non-muscle invasive bladder cancer
Conditions
Interventions
Low risk NMIBC patients:N/A
High-Intermediate risk NMIBC patients:N/A
Sponsors
Fudan University Shanghai Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients who are diagnosed with NMIBC; 2.Age >= 18 years old, male or female; 3.Patients who are proposed to receive clinical treatment including TURBT and/or infusion therapy; 4.It can provide 100mL morning urine samples before initial TURBT, before induced infusion therapy,and before cystoscopy within the follow-up time. For patients undergoing secondary TURBT,100mL morning urine sample needs to be provided before secondary TURBT; 5.Sign informed consent form, willing to comply with the agreement content, good compliance, and participate in follow-up assessment.
Exclusion criteria
Exclusion criteria: 1.NMIBC patients who progressed to MIBC after recurrence; 2.Patients who were diagnosed with other malignancies or received any anti-cancer treatment within 5 years; 3.Patients with other genitourinary tumors (prostate or kidney cancer); 4.Patients who participated in clinical trials of drugs within 3 months before enrollment; 5.The investigator believes that there may be any conditions that increase the risk to the subjects or interfere with clinical trial; 6.Patients whose samples and clinical data are incomplete for all kinds of reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Urine DNA-based detection of minimal residual disease; | — |
Countries
China
Contacts
Public ContactYe Dingwei
Fudan University Shanghai Cancer Center
Outcome results
None listed